Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Hormonal Therapy in HR+ Localized Inflammatory Breast Cancer
NCT02971748Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2017
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in inflammatory breast cancer (IBC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Disease Free Survival and Participants With Treatment-Related Adverse Events. Started Jan 2017; status: active, not recruiting.
02
Drugs
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT02971748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02971748.